NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

November 1, 2016

To
B S E Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

Scrip Code: 524558

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: NEULANDLAB
Series: EQ

Dear Sirs,

Results Release and Earnings Call Notice

We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q2 FY 2017 Earnings Call details, for your information and records.

Thanking you,

Yours faithfully,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Earning Conference Call:

Neuland Laboratories Limited will announce its results for the second quarter ended September 30th, 2016 on Friday, November 4th, 2016. The results will also be made available on the website of the Company, www.neulandlabs.com.

Following the announcement, the management of the Company will host an Earnings Call on **Monday, November 7th, 2016** at **0930 hrs.** The details of the earnings call are:

Date: November 7,2016 Time: 0930 Hrs

Dial-in Number: +91 22 3960 0644

Secondary Number: +91 22 6746 4144

You can also click here for the diamond pass and calendar invite to your inbox

Other Numbers:

Local Access Number

3940 3977(Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune)

International Toll Free Number

USA - 18667462133 | UK - 08081011573 | Singapore - 8001012045 | Hong Kong - 800964448

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANDLAB)

For over 32 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 48 U.S. drug master files (DMFs) and a total of around 400 DMFs in the European Union (EU) and other countries. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, Anvisa (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

For Queries:

Neuland: ir@neulandlabs.com **or Ankit Gupta:** ankitgupta@christensenir.com